However, inhibition of lactation is expected because ropinirole inhibits secretion of prolactin in humans.

If a dose is missed, advise patients not to double their next dose. Side effects of Requip and Neurontin that are similar include dizziness, drowsiness, anxiety, double vision or vision problems. RLS is a neurologic disorder that affects sensation and movement in the legs and causes the legs to feel uncomfortable. Among those patients receiving both REQUIP and L-dopa in advanced Parkinson’s disease studies, 10.1% (21 of 208) were reported to experience hallucinations, compared with 4.2% (5 of 120) of patients treated with placebo and L-dopa.The incidence of hallucination was increased in elderly patients (i.e., older than 65 years) treated with extended-release REQUIP [see Postmarketing reports indicate that patients with Parkinson’s disease or RLS may experience new or worsening mental status and behavioral changes, which may be severe, including psychotic-like behavior during treatment with REQUIP or after starting or increasing the dose of REQUIP. Medicines that interact with ropinirole may either decrease its effect, affect how long it works for, increase side effects, or have less of an effect when taken with ropinirole.

In some patients in clinical trials, blood pressure changes were associated with the emergence of orthostatic symptoms, bradycardia, and, in one case in a healthy volunteer, transient sinus arrest with syncope [see The mechanism of orthostatic hypotension induced by ropinirole is presumed to be due to a D2-mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance.

Having one of these conditions does not mean you have or will develop the other condition.You should not be taking more than 1 medicine containing ropinirole. In these studies, 11 of the 55 patients (20%) receiving REQUIP and 3 of the 26 patients (12%) who had post-dose blood pressure assessments following placebo, experienced an orthostatic blood pressure decrease of at least 40 mm Hg systolic and/or at least 20 mm Hg diastolic.In Phase 1 trials of REQUIP with healthy volunteers who received single doses on more than one occasion without titration, 7% had documented symptomatic orthostatic hypotension.

Taking ropinirole with other drugs that make you sleepy can worsen this effect.

Patients were eligible for enrollment if they presented with bradykinesia and at least tremor, rigidity, or postural instability. Patients previously receiving stable doses of selegiline, amantadine, and/or At the end of 6 months, the percentage of responders was greater on REQUIP than on placebo and the difference was statistically significant (Table 8).Based on the protocol-mandated reductions in L-dopa dosage with escalating doses of REQUIP, patients treated with REQUIP had a 19.4% mean reduction in L-dopa dosage while patients treated with placebo had a 3% reduction. Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.. Orthostatic Hypotension, A Form Of Low Blood Pressure If experienced, these tend to have a Less Severe expression 1.

Inform patients who experience these or similar reactions to immediately contact their healthcare professional [see Alert patients to the potential sedating effects caused by REQUIP, including somnolence and the possibility of falling asleep while engaged in activities of daily living. The highest dose not associated with this finding (15 mg/kg/day) is 3 times the MRHD on a mg/m² basis.Ropinirole was not mutagenic or clastogenic in in vitro (Ames, chromosomal aberration in human lymphocytes, mouse lymphoma tk) assays, or in the in vivo mouse micronucleus test.When administered to female rats prior to and during mating and throughout pregnancy, ropinirole caused disruption of implantation at oral doses of 20 mg/kg/day (8 times the MRHD on a mg/m² basis) or greater.

It is also used to treat Parkinson’s disease.Having one of these conditions does not mean you have or will develop the other condition.You should not be taking more than 1 medicine containing ropinirole. Requip (ropinirole)." Following a 24-week, REQUIP and REQUIP XL can cause serious side effects including:Having one of these conditions does not mean you have or will develop the other condition.You should not be taking more than 1 medicine containing ropinirole. The most common adverse reaction in patients treated with REQUIP (incidence at least 2% greater than placebo) of sufficient severity to cause discontinuation was dizziness.Table 4 lists treatment-emergent adverse reactions that occurred in at least 2% of patients with advanced Parkinson's disease (with L-dopa) treated with REQUIP who participated in the double-blind, placebo-controlled trials and were numerically more common than the incidence for placebo-treated patients. Patients on REQUIP should be monitored for signs and symptoms of orthostatic hypotension, especially during dose escalation, and should be informed of the risk for syncope and hypotension [seeAlthough the clinical trials were not designed to systematically monitor blood pressure, there were individual reported cases of orthostatic hypotension in early Parkinson’s disease (without L-dopa) in patients treated with REQUIP. There is thus the potential for inducers or inhibitors of this enzyme to alter the clearance of ropinirole.

You may report side effects to FDA at 1-800-FDA-1088.Taking ropinirole with other drugs that make you sleepy can worsen this effect. Follow the directions on your prescription label.

in combination with REQUIP or when taking a concomitant medication (e.g., ciprofloxacin) that increases plasma levels of ropinirole [seeAdvise patients that they may experience syncope and may develop hypotension with or without symptoms such as dizziness, nausea, syncope, and sometimes sweating while taking REQUIP, especially if they are elderly.